Nancy Whiting
Director/Board Member en CARIBOU BIOSCIENCES, INC. .
Fortuna: - $ al 29/02/2024
Perfil
Currently, Nancy C.
Whiting is Chief Executive Officer & Director at Recludix Pharma, Inc. She is also on the board of Caribou Biosciences, Inc. and Boundless Bio, Inc.
Dr. Whiting previously occupied the position of President, Secretary & Director at Cascadian Therapeutics LLC and Executive VP-Strategy, Alliances & Communications at Seagen Inc.
Dr. Whiting received a graduate degree from the University of Washington and an undergraduate degree from the University of British Columbia.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
20/02/2024 | 0 ( -.--% ) | - $ | 29/02/2024 | |
Boundless Bio, Inc.
Boundless Bio, Inc. BiotechnologyHealth Technology Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company was founded by Vineet Bafna, Paul Mischel, Benjamin F. Cravatt, and Jonathan E. Lim on April 10, 2018 and is headquartered in San Diego, CA. -.--% | 27/03/2024 | 0 ( -.--% ) | - $ | 29/02/2024 |
Cargos activos de Nancy Whiting
Empresas | Cargo | Inicio |
---|---|---|
CARIBOU BIOSCIENCES, INC. | Director/Board Member | 24/08/2021 |
Recludix Pharma, Inc.
Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | Chief Executive Officer | 01/09/2021 |
Boundless Bio, Inc.
Boundless Bio, Inc. BiotechnologyHealth Technology Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company was founded by Vineet Bafna, Paul Mischel, Benjamin F. Cravatt, and Jonathan E. Lim on April 10, 2018 and is headquartered in San Diego, CA. | Director/Board Member | 02/10/2023 |
Antiguos cargos conocidos de Nancy Whiting.
Empresas | Cargo | Fin |
---|---|---|
CASCADIAN THERAPEUTICS INC (USA) | President | - |
SEAGEN INC. | Public Communications Contact | - |
Formación de Nancy Whiting.
University of Washington | Graduate Degree |
University of British Columbia | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
CARIBOU BIOSCIENCES, INC. | Health Technology |
Health Technology |
Empresas privadas | 3 |
---|---|
Seagen Inc.
Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
Cascadian Therapeutics LLC
Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Cascadian Therapeutics LLC is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutic products for the treatment of cancer. Its product ONT-380, is an orally active and selective small-molecule HER2 inhibitor. The firm also develops preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on September 7, 2007 and is headquartered in Bothell, WA. | Health Technology |
Recludix Pharma, Inc.
Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | Commercial Services |